Facebook
Twitter
LinkedIn
Forward
ASH 2019 Highlights
Description
The care of patients with hematologic malignancies is evolving rapidly. This continuing medical education activity will discuss new developments in the diagnosis and treatment of hematologic malignancies, as presented at the 2019 Annual Meeting of the American Society of Hematology (ASH).
At this one-day course, faculty will share the latest updates in lymphoma, leukemia, multiple myeloma, coagulation disorders, and stem cell transplantation. Through case-based presentations and Q&A, attendees will gain a deeper understanding of emerging treatments available for blood cancers and blood disorders and learn how these new therapies can be integrated into daily practice.
Target Audience
This activity is directed toward hematologists, medical oncologists, internists, nurse practitioners, oncology nurses, and other interested healthcare providers.
Learning Objectives
At the conclusion of this course, attendees will be able to:
- Provide an overview and highlight the recent medical advances presented at the 2019 Annual Meeting of the American Society of Hematology, which will help physicians achieve better patient outcomes.
- Recognize appropriate management and treatment options for hematologic malignancies and utilize these approaches in routine clinical practice for stem cell transplantation, lymphoma, multiple myeloma, acute lymphocytic leukemia and chronic myelogenous leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, acute promyelocytic leukemia and myelodysplastic syndrome.
- Recognize new therapies and approaches in non-malignant hematology.
About the Center for Hematologic Oncology at Dana-Farber/Brigham and Women's Cancer Center
We offer advanced, specialized care for patients with all types of hematologic malignancies, including leukemia and similar bone marrow disorders, lymphoma, multiple myeloma, Waldenström’s macroglobulinemia, and other related blood disorders.
Dana-Farber/Brigham and Women’s Cancer Center is at the forefront of stem cell transplantation, performing more than 500 transplants each year. Our team of specialists are national leaders in basic and clinical research designed to bring cutting-edge, innovative therapies to patients with blood cancers. The program is committed to working closely with referring oncologists to jointly devise clinical strategies to improve the care of our patients.
Additional Information
Dana-Farber/Brigham and Women's Cancer Center and Partners HealthCare System
Ann S. LaCasce, MD, MMSc - Course Director
Director, Dana-Farber/Partners CancerCare Hematology-Medical Oncology Fellowship Program,
Medical Oncologist, Adult Lymphoma Program,
Dana-Farber/Brigham and Women’s Cancer Center;
Associate Professor of Medicine, Harvard Medical School
Nathan T. Connell, MD, MPH
Chief of Hematology, Brigham and Women's Faulkner Hospital;
Assistant Professor of Medicine, Harvard Medical School
Matthew S. Davids, MD, MMSc
Associate Director, Center for Chronic Lymphocytic Leukemia,
Dana-Farber/Brigham and Women’s Cancer Center;
Assistant Professor of Medicine, Harvard Medical School
Daniel J. DeAngelo, MD, PhD
Chief, Division of Leukemia,
Dana-Farber/Brigham and Women’s Cancer Center;
Professor of Medicine, Harvard Medical School
Eric D. Jacobsen, MD
Clinical Director, Adult Lymphoma Program,
Director, Histiocyte Disorders Center,
Dana-Farber/Brigham and Women’s Cancer Center;
Assistant Professor of Medicine, Harvard Medical School
Clifton C. Mo, MD
Director, Autologous Stem Cell Transplantation for Multiple Myeloma,
Dana-Farber/Brigham and Women’s Cancer Center
Rizwan Romee, MD
Director, Haploidentical Donor Transplantation Program,
Dana-Farber/Brigham and Women’s Cancer Center;
Associate Professor of Medicine, Harvard Medical School
Richard M. Stone, MD
Chief of Staff, Dana-Farber Cancer Institute;
Director, Translational Research, Adult Leukemia Program,
Dana-Farber/Brigham and Women’s Cancer Center;
Professor of Medicine, Harvard Medical School
Partners HealthCare System is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Partners HealthCare System designates this live activity for a maximum of 5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credits
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under provider number CEP 5832 to award 5.0 continuing education contact hours through the California Board of Registered Nursing. Approval Period: December 2017-December 2020.
LLS maintains responsibility for the program. Upon completion of this program and submission of the activity evaluation, a certificate of completion will be provided to you within 30 days.
Available Credit
- 5.00 AMA PRA Category 1 Credit™
- 5.00 Participation
Price
Registration is now closed. On-site registrations will be accepted but please note: cash and credit cards are not accepted on-site. Checks only.
Registration Fee: non-refundable, includes course materials, continental breakfast, lunch, and complimentary parking
- $75.00 through December 30, 2019
- $85.00 after December 30, 2019
For questions regarding registration, please contact the Partners Office of Continuing Professional Development at partnerscpd@partners.org.
For questions regarding the conference, please call 1-800-553-3787.
If you have any food allergies, or if you require accommodations such as an ASL interpreter, materials in an alternative format, or wheelchair access, please contact our course coordinator at kwooten@partners.org or call 1-800-553-3787 before the live event.